U.S. Paper and Forestry Products Stock News

Ocugen (OCGN) has attracted fresh attention after recent trading left the shares at US$1.95, against a market value of about US$648.8m. This has prompted investors to reassess how its pipeline and financials line up. See our latest analysis for Ocugen. Recent trading has been choppy, with a 1-day share price return of 1.56% set against a 7-day share price return decline of 14.85%. However, the 90-day share price return of 35.42% and 1-year total shareholder return of 163.87% point to momentum...

Wondering if Moderna at US$53.54 is a bargain or a value trap? This article walks through what the numbers are really saying about the stock. The share price return sits at 2.2% over 7 days, 6.5% over 30 days, 73.5% year to date and 70.1% over the last year, alongside a 64.0% decline over 3 years and a 59.1% decline over 5 years. Recent headlines around Moderna have focused on its position in the pharmaceutical and biotech space and how investors are reassessing companies in this part of the...

In March 2026, Uranium Energy Corp. reported state approvals and startup of three new header houses at Christensen Ranch in Wyoming, alongside an NRC docket for its planned U.S. uranium conversion facility, advancing both production capacity and licensing progress for refining and conversion. These steps move the company closer to its goal of becoming a fully vertically integrated American nuclear fuel supplier, potentially enhancing control over the domestic fuel chain and mitigating...

Event driven move in Paymentus Holdings (PAY) Paymentus Holdings (PAY) is back on investor radars after recent trading activity highlighted a mixed return profile, with gains over the past month set against a roughly 21% decline over the past 3 months. See our latest analysis for Paymentus Holdings. At a share price of US$25.10, Paymentus sits between a modest 30 day share price return and a much weaker 90 day share price return, while the 3 year total shareholder return above 100% points to...

Investor activism meets softer quarterly results AutoNation (AN) is facing closer investor scrutiny after a softer Q4, with revenue down 3.9% year on year and earnings missing analyst estimates, even as After-Sales and Customer Financial Services reported record gross profit. See our latest analysis for AutoNation. AutoNation's share price has softened recently, with a 30 day share price return of 1.64% decline and a 90 day share price return of 8.82% decline, even as the 1 year total...

Wondering if Oncolytics Biotech at around US$0.95 is offering value or just extra risk? This article breaks down what that price tag could really mean for you. The stock is roughly flat year to date with a 3.4% decline. It has returned 54.7% over the last year, which can raise questions about how much potential or risk might already be reflected in the price. Recent coverage has focused on Oncolytics Biotech's progress as a clinical stage cancer therapy developer and the implications of its...

Valero Energy (NYSE:VLO) is facing a worker lawsuit that alleges negligence after the recent explosion at its Port Arthur refinery. The suit claims gross negligence related to safety practices and working conditions at one of Valero's largest facilities. This legal action adds fresh scrutiny to the company's operational risk management and potential liability exposure. Valero is one of the largest independent refiners in the US, with operations that supply transportation fuels and other...

IDEAYA Biosciences recently updated investors on the timing of topline data from its Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma, indicating that the database lock occurred in the first half of April and that a live webcast will follow to discuss the results. This combination of a clarified data-readout timeline and a planned investor-and-expert webcast highlights how the trial’s outcome could meaningfully shape perceptions of IDEAYA’s clinical...

Maze Therapeutics reported promising Phase II results for its APOL1-mediated kidney disease candidate MZE829. The company plans to move MZE829 into pivotal testing, targeting the same indication as Vertex Pharmaceuticals' inaxaplin program. This development introduces a new competitor to NasdaqGS:VRTX in the APOL1-mediated kidney disease space. Vertex Pharmaceuticals, listed as NasdaqGS:VRTX, is known for its focus on serious diseases with high unmet need, and inaxaplin is one of its key...

Worthington Enterprises (WOR) has reported a busy quarter, with Q3 2026 revenue at US$378.7 million and basic EPS of US$0.93, alongside trailing 12 month EPS of US$2.27 that sits against reported earnings growth of 84.3% over the past year and a longer term 5 year earnings decline of 47.8% per year. Over recent quarters the company has seen revenue move from US$274.0 million in Q2 2025 to US$304.5 million in Q3 2025 and then to US$378.7 million in Q3 2026. Quarterly basic EPS shifted from...

Cipher Digital (CIFR) has been drawing attention after its recent rebrand from Cipher Mining Inc., shifting the focus toward a broader digital infrastructure story that is built around bitcoin mining and high performance compute hosting in the United States. See our latest analysis for Cipher Digital. The recent rebrand comes as Cipher Digital’s share price sits at US$15.88, with short term momentum reflected in a 1-day share price return of 6.72% and a 1-year total shareholder return that is...

Core & Main (CNM) drew investor attention after its latest quarterly report, which paired a 16th consecutive year of sales growth with a cautious 2% to 3% net sales outlook for fiscal 2026. See our latest analysis for Core & Main. The cautious 2% to 3% net sales outlook has weighed on sentiment in the short term, with the 30 day share price return of 7.43% and 90 day share price return of 6.68% pointing to cooling momentum despite a 3 year total shareholder return of 124.76%. If Core & Main’s...

If you are wondering whether BioCryst Pharmaceuticals at US$9.40 still offers value, it helps to start by lining up the recent share performance with what the fundamentals suggest the stock might be worth. Over the short term, the share price return sits at 2.6% over 7 days, 24.0% over 30 days and 25.3% year to date, with a 20.5% return over 1 year and 9.8% over 3 years, compared with a 5 year return of a 7.6% decline. These moves are occurring as investors continue to respond to ongoing...

Over the last 7 days, the United States market has remained flat, yet it has risen by 16% over the past year with expectations of earnings growing annually by a similar rate in the coming years. In this context of steady growth, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and potential to outperform these promising market conditions.

In the last week, the United States market has stayed flat, although it is up 16% over the past year with earnings forecasted to grow by 16% annually. In this environment, identifying stocks trading below their estimated intrinsic value can present opportunities for investors seeking potential growth at a reasonable price.

If you are wondering whether Pitney Bowes at around US$10.91 is still offering value or if the easy part of the move is behind it, the starting point is understanding how its current price lines up with different valuation checks. The stock has posted returns of 11.3% over the last 7 days, 5.1% over the past month, 5.6% year to date and 18.6% over the last year, while the 3 year return is very large and the 5 year return sits at 61.5%. Recent headlines have focused on Pitney Bowes in the...

Coca-Cola (KO) is committing up to US$650 million to expand its Fairlife facility in Michigan, adding 245,000 square feet of production space and 150 jobs, a meaningful operational development for long term shareholders. See our latest analysis for Coca-Cola. Coca-Cola shares trade at US$75.25 after a 7.33% 90 day share price return and 8.87% year to date share price return. The 5 year total shareholder return of 65.70% points to steady long term compounding, suggesting recent momentum has...

If you are wondering whether Redwire's current share price lines up with its underlying worth, this article will walk you through what the numbers are actually saying. Redwire's share price closed at US$9.16 recently, with a 12.8% return over the last 30 days, a 1.4% return year to date, and a 17.1% decline over the past year, while the 3-year return sits at a very large gain. Recent coverage has focused on Redwire within the Aerospace and Defense space, with attention on how the business is...

In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 16%, with earnings forecasted to grow at a similar rate annually. In this context of steady growth, stocks with strong insider ownership can be particularly appealing as they often indicate confidence in a company's future prospects and alignment between management and shareholders.

Central Bancompany (CBC) has just been added to a wide range of Russell value and broad market indexes, an inclusion that often shifts how institutional investors and index funds look at the stock. See our latest analysis for Central Bancompany. At a share price of US$23.72, Central Bancompany has seen modest short term softness, with a 30 day share price return of a 2.43% decline. However, the 1 year total shareholder return of 73.02% and 5 year total shareholder return of 134.52% point to...

Earlier this year, Proto Labs released its “Innovation in Manufacturing 2026” report, outlining how manufacturers are moving beyond Industry 4.0 toward Industry 5.0 by using artificial intelligence to accelerate product development and production. The report underscores Proto Labs’ ambition to shape each stage of the product life cycle with advanced digital manufacturing technologies, positioning its platform as an enabler of faster, more efficient innovation for customers under pressure to...

In the last week, the market has stayed flat, but over the past 12 months, it has risen by 16%, with earnings projected to grow annually at a similar rate. In light of these conditions, identifying stocks with solid fundamentals and growth potential is crucial for investors seeking opportunities. Penny stocks may be an outdated term, yet they represent a valuable investment area for those interested in smaller or newer companies that offer affordability and potential upside when backed by...

In the last week, the United States market has remained flat, though it has risen by 16% over the past year with earnings expected to grow annually at the same rate. In this environment, identifying stocks with strong fundamentals and growth potential can offer investors opportunities to uncover hidden treasures in a dynamic market landscape.

This article examines whether Pool, at around US$202 a share, might represent a potential bargain or a value trap, and explores what the current price could be implying about the company. The stock has had a difficult period, with returns of a 1.1% decline over 7 days, 6.9% decline over 30 days, 12.0% decline year to date, and 36.5% decline over the past year. This may have influenced how the market is viewing its risk and return profile. Recent commentary on Pool has centered on its share...